Tag: pharmaceuticals

  • FDA Approves Pneumococcal Disease Vaccine for Older Adults

    At the end of December, the U.S. Food and Drug Administration (FDA) approved the vaccine Prevnar 13 for people ages 50 years and older to prevent pneumonia and invasive disease caused by the bacterium Streptococcus pneumoniae (S. pneumoniae). The drug is manufactured by the Wyeth Pharmaceuticals division of Pfizer Inc. Pneumococcal pneumonia is caused when…

  • Emergent BioSolutions, Abbott Labs End Collaboration

    As reported yesterday, Emergent BioSolutions Inc. in Rockville, Maryland has started a phase 2 clinical study of its drug candidate TRU-016, a program conducted in partnership with pharmaceutical manufacturer Abbott Laboratories. Emergent BioSolutions now says that Abbott Laboratories has ended the partnership agreement to develop and commercialize the compound. Daniel J. Abdun-Nabi, president of Emergent…

  • Clinical Trial to Test Leukemia Drug Combination [UPDATED]

    UPDATE, 29 December 2011: Emergent Biosolutions, Abbott Labs End Collaboration Emergent BioSolutions Inc. in Rockville, Maryland has started a phase 2 clinical study of its drug candidate TRU-016 in combination with the chemotherapy drug bendamustine for patients with relapsed chronic lymphocytic leukemia (CLL). The company is developing TRU-016 in a partnership with Abbott Laboratories. Chronic…

  • NIH Establishes Medical Translational Science Center

    The federal 2012 fiscal year spending bill passed by Congress and signed by President Obama before Christmas includes approval for National Institutes of Health (NIH) to form a new research center devoted to turning discoveries in the lab into new drugs, diagnostics, and devices. The National Center for Advancing Translational Sciences (NCATS), with a budget…

  • Baxter, Momenta to Partner on Biosimilars

    Pharmaceutical and medical device maker Baxter International and biotechnology company Momenta Pharmaceuticals have agreed to collaborate on development of follow-on biologic drugs, also known as biosimilars. The deal valued at at least $33 million is expected to close in the first quarter of 2012. Under the agreement, Baxter in Deerfield, Illinois, will make an up-front…

  • Biotech Lands $30 Million Late Stage Investment

    Acceleron Pharma Inc. in Cambridge, Massachusetts says it raised $30 million in private financing from its current investors and one of its drug development partners. The funds, says Acceleron, will advance its clinical stage drug pipeline, as well as its overall research agenda. The company develops therapies based on the transforming growth factor beta (TGF-beta)…

  • Engineered HIV/AIDS Vaccine Approved for Clinical Trials

    A vaccine designed to prevent HIV infection based on a genetically engineered virus has received approval by the U.S. Food and Drug Administration to start clinical trials. The vaccine is a product of a joint venture between Universiy of Western Onatrio in London and the Canadian subsidiary of Korean pharmaceutical venture company Sumagen. Chil-Yong Kang…

  • Life Science Venture Fund Raises $313 Million

    Burrill & Company in San Francisco announced today a new life sciences investment fund with commitments so far totaling $313 million. The company says its Burrill Capital Fund IV plans to make early to late stage investments in therapeutics, diagnostics, medical devices, health care delivery, wellness, and digital health. CEO G. Steven Burrill says the…

  • Clinical Study IDs Potential Antidepressant Predictor

    Researchers at Loyola University Medical Center near Chicago have found a method that can help predict if an antidepressant will work on a patient with depression. Loyola psychiatry professor Angelos Halaris and colleagues reported their work earlier this year at the annual meeting of the Society of Biological Psychiatry. The study involved 35 patients who…

  • GSK, University of Dundee Partner on Huntington’s Disease

    University of Dundee in Scotland and the pharmaceutical company GlaxoSmithKline (GSK) will collaborate in research to tackle Huntington’s disease, an inherited brain disorder. The joint project is valued at more than £1 million ($US 1.6 million). Dundee medical professor Susann Schweiger, who has discovered a mechanism that controls production of the disease-causing protein involved in…